Hyperuricemia - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 62 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hyperuricemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hyperuricemia - Pipeline Review, H2 2014', provides an overview of the Hyperuricemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperuricemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperuricemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperuricemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hyperuricemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hyperuricemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperuricemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperuricemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperuricemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperuricemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperuricemia - Overview 8
Pipeline Products for Hyperuricemia - Comparative Analysis 9
Hyperuricemia - Therapeutics under Development by Companies 10
Hyperuricemia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperuricemia - Products under Development by Companies 15
Hyperuricemia - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
Chugai Pharmaceutical Co., Ltd. 17
CymaBay Therapeutics, Inc. 18
Kissei Pharmaceutical Co., Ltd. 19
LG Life Sciences, Ltd. 20
Nippon Chemiphar Co., Ltd. 21
Polaris Group 22
Takeda Pharmaceutical Company Limited 23
Teijin Pharma Limited 24
Hyperuricemia - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
arhalofenate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
febuxostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
febuxostat XR - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
JPH-367 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
KGO-2142 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KGO-2173 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KUX-1151 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
LC-350189 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NC-2500 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RDEA-3170 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
UR-1102 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Uricase-PEG 20 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
XEN-102 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Hyperuricemia - Recent Pipeline Updates 52
Hyperuricemia - Dormant Projects 54
Hyperuricemia - Discontinued Products 55
Hyperuricemia - Product Development Milestones 56
Featured News & Press Releases 56
Nov 01, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Uloric 56
Apr 11, 2012: Teijin Pharma And Menarini Sign Distribution Agreement For Marketing Of Febuxostat 56
Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat 57
Jul 28, 2011: Teijin Pharma Launches Febuxostat In Korea 57
May 13, 2011: Teijin Pharma To Launch FEBURIC In Japan 58
Apr 18, 2011: Teijin Pharma Expands Global Market For TMX-67 58
Jan 21, 2011: Teijin Pharma Receives Approval Of TMX-67 For Treating Hyperuricemia In Japan 59
Oct 27, 2010: Teijin Pharma Launches TMX-67 In Canada 59
Mar 09, 2010: Menarini Launches ADENURIC (Febuxostat) In Europe 60
Mar 05, 2010: Launch by Menarini and Ipsen of Adenuric (febuxostat) in France for the treatment of chronic hyperuricemia in gout 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products under Development for Hyperuricemia, H2 2014 8
Number of Products under Development for Hyperuricemia - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Hyperuricemia - Pipeline by AstraZeneca PLC, H2 2014 16
Hyperuricemia - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014 17
Hyperuricemia - Pipeline by CymaBay Therapeutics, Inc., H2 2014 18
Hyperuricemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 19
Hyperuricemia - Pipeline by LG Life Sciences, Ltd., H2 2014 20
Hyperuricemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2014 21
Hyperuricemia - Pipeline by Polaris Group, H2 2014 22
Hyperuricemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 23
Hyperuricemia - Pipeline by Teijin Pharma Limited, H2 2014 24
Assessment by Monotherapy Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 29
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Hyperuricemia Therapeutics - Recent Pipeline Updates, H2 2014 52
Hyperuricemia - Dormant Projects, H2 2014 54
Hyperuricemia - Discontinued Products, H2 2014 55